Suven Life Sciences announced on Monday that it has received two product patents, one from Europe and the other from New Zealand. These grants were received for the New Chemical Entities (NCE) for the treatment of neurodegenerative disease. These patents are valid till 2027 and 2025.
With the two new patents, Suven now has a total of ten granted patents in Europe and 11 in New Zealand.
